1 min read
As pharmaceutical companies continue expanding into Australia, regulatory expectations around dossier quality and submission readiness are becoming increasingly stringent. While inclusion in the Australian Register of Therapeutic Goods (ARTG) remains a key objective for sponsors, approval success now depends on far more than simply compiling documents.
In 2026, the Therapeutic Goods Administration (TGA) is placing greater emphasis on data integrity, consistency across submission modules, GMP alignment, and lifecycle readiness. As a result, dossier due diligence has become a critical step in reducing regulatory risk and avoiding avoidable delays.
Dossier due diligence refers to the structured review and validation of submission documents before regulatory filing.
For ARTG submissions, the TGA typically evaluates:
- Completeness and consistency across CTD/eCTD modules
- Accuracy of Australia-specific Module 1 (M1) documentation
- Alignment between quality, safety, and efficacy data
- GMP clearance status and supporting evidence
- Product labeling and Product Information (PI) compliance
- Readiness for lifecycle changes and post-approval maintenance
Even when technical data is strong, inconsistencies or incomplete localization can trigger regulatory queries and prolong review timelines.
Problem
Many sponsors continue to face approval bottlenecks due to gaps in dossier preparation and regulatory planning.
1. Inconsistent Submission Data
Differences between modules, outdated information, or formatting discrepancies often lead to TGA queries.
2. Incomplete Module 1 Localization
Global dossiers may not fully address Australia-specific administrative and regulatory requirements.
3. GMP Clearance Challenges
Missing or misaligned GMP evidence remains one of the most common reasons for submission delays.
4. Limited Submission Readiness Assessment
Without a structured due diligence review, sponsors risk multiple review cycles and unnecessary rework.
5. Lack of Lifecycle Planning
Post-approval requirements such as variations, renewals, and labeling updates are often overlooked during submission preparation.
These challenges can significantly impact approval timelines, operational efficiency, and market entry planning.
Freyr Solution
Freyr supports pharmaceutical sponsors with comprehensive dossier due diligence and regulatory support for Australia submissions, including:
Regulatory gap analysis and submission readiness assessment
Detailed dossier quality and consistency review
TGA-compliant Module 1 preparation and localization
CTD/eCTD compilation and publishing support
GMP clearance coordination and compliance review
Regulatory query handling and lifecycle management (LCM) support
By combining regulatory expertise with execution-focused support, Freyr helps sponsors improve dossier quality, reduce approval delays, and strengthen long-term compliance management.
For global pharmaceutical companies, adapting international dossiers to Australia-specific expectations can be resource-intensive and operationally complex.
Freyr helps bridge this gap by aligning global regulatory documentation with TGA requirements while supporting efficient multi-market regulatory execution and lifecycle compliance.
In Australia, successful ARTG submissions depend not only on scientific data—but on the quality, consistency, and regulatory readiness of the dossier itself.
Is your dossier truly submission-ready—or simply submission-complete?
Connect with Freyr to strengthen your dossier due diligence strategy and improve ARTG submission readiness for Australia
